A medicine may already be approved for marketing in some countries, but not approved in other countries for several years or ever.
TannerMAP partners with biopharmaceutical companies to enable patients access to medicines not yet approved in their countries.
Responding to Emerging Opportunities
A European pharmaceutical company was prioritizing which markets to enter and Thailand ranked as a lower registration priority than other countries.
WHY PARTNER WITH TANNERMAP ON A MANAGED ACCESS PROGRAM?
Expand access to more markets and earlier than planned by utilizing TannerMAP’s global GDP-compliant supply chain and regulatory expertise to import medicines into countries where marketing is not yet approved.
Reduce the administrative workload by authorizing TannerMAP to manage the requirements of validating patients and institutions that participate in a Managed Access Program.
Gain broader insights on product efficacy and demand to help inform future commercialization strategies and complement clinical trial findings by tapping into TannerMAP’s data collection and reporting services.
Build awareness with physicians, hospitals, pharmacists, regulators and patients by letting TannerMAP help develop and deliver a customized and compliant Managed Access Program.